

THEY HAVE PLACES TO GO AND THINGS TO DO

COVID-19 can get
in the way



Help protect more patients by **co-administering
COVID-19 and Flu vaccines** today.^{1-7*}

*As stated in the Australian Immunisation Handbook; in individuals aged 5 years and over only

Resources available



2025 ATAGI
clinical guidance
on COVID-19
vaccines



COMIRNATY
JN.1 Pre-filled
syringe fact card



COMIRNATY
JN.1 Formulations
Guide

COVID-19 remains a significant public health risk in Australia²

In 2024 compared with influenza, COVID-19 caused²:


50% More ICU admissions overall

70% More hospitalisations in those aged 16 and older

5x Number of deaths in those aged 70 and over

However, the COVID-19 vaccination rate in older Australians remains worryingly low^{3,4}:

Proportion of over 65s vaccinated in the last 12 months*



*as at March 2025

Source: Australian Government Department of Health and Age Care and NCIRS

How can you help ensure that your patients are up to date with their COVID-19 vaccinations?


Co-administering COVID-19 and influenza is a simple and valuable method for improving vaccine uptake⁸



COVID-19 vaccine can be **co-administered with any other vaccine** in individuals **aged 5 years and older** in the same visit¹



No increase in adverse events observed when co-administering COVID-19 and influenza vaccines (limited data available)⁸



Order copies of the Adult Vaccination Guide to help your patients stay on track with their recommended vaccinations.




Order here

Your recommendation matters^{9,10}

A recommendation from a healthcare professional is one of the primary reasons your patients get vaccinated.

You can play an important role in helping to ensure that eligible patients receive an updated COVID-19 vaccine.

Download the **Vaccine Conversation Starter** to support you in having conversations with your patients.



Most frequent adverse reactions to COMIRNATY include injection site pain, fatigue, headache, myalgia, chills and arthralgia. There have been very rare reports of myocarditis and pericarditis.

▼ This vaccine is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at: www.tga.gov.au/safety/reporting-problems.



PBS Information: This product is not listed on the PBS and is not listed on the NIP

Before prescribing, please review the Approved Product Information available at pfi.sr/comirnatyp or by scanning the QR code.

References: 1. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook – COVID-19. Available at: <https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/covid-19#recommendations>. Accessed 27 February 2025. 2. Australian Centre for Disease Control. Australian Respiratory Surveillance Report 17 – 18 November to 15 December 2024. Available at: <https://www.health.gov.au/resources/publications/australian-respiratory-surveillance-report-17-18-november-to-15-december-2024?language=en>. Accessed 27 February 2025. 3. Australian Government Department of Health and Aged Care. COVID-19 vaccine rollout update – 14 March 2025. Available at: <https://www.health.gov.au/resources/publications/covid-19-vaccine-rollout-update-14-march-2025?language=en>. Accessed 27 April 2025. 4. National Centre for Immunisation Research and Surveillance. Influenza vaccination coverage data. Available at: <https://ncirs.org.au/influenza-vaccination-coverage-data>. Accessed 27 February 2025. 5. COMIRNATY® JN.1 (bretovameran) Product Information. 6. Australian Technical Advisory Group on Immunisation. Australian Immunisation Handbook – influenza. Available at: <https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/influenza-flu>. Accessed 14 March 2025. 7. Australian Technical Advisory Group on Immunisation. ATAGI statement on the administration of seasonal influenza vaccines in 2025. Available at: https://www.health.gov.au/sites/default/files/2025-03/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2025_0.pdf. Accessed 21 March 2025. 8. World Health Organisation. Coadministration of seasonal inactivated influenza and COVID-19 vaccines. 21 October 2021. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-coadministration-influenza-vaccines. Accessed 13 February 2025. 9. Briggs L, et al. *Vaccine*. 2019;37:4454–4459. 10. Bui TNT, et al. *Int J Pharm Pract*. 2023;31(3):337–340.

COMIRNATY® is a registered trademark of BioNTech SE, used under license.

© 2025 Pfizer Australia Pty Ltd. Sydney, Australia. All rights reserved.

Pfizer Medical Information: 1800 675 229. PP-CMR-AUS-0401. COM-003669-00. 05/25.

COMIRNATY®
JN.1 bretovameran

BIONTECH

Pfizer